Forward Pharma traded at $300.00 this Monday February 5th, decreasing $100.50 or 25.09 percent since the previous trading session. Looking back, over the last four weeks, Forward Pharma lost 27.88 percent. Over the last 12 months, its price fell by 61.04 percent. Looking ahead, we forecast Forward Pharma to be priced at 284.46 by the end of this quarter and at 242.51 in one year, according to Trading Economics global macro models projections and analysts expectations.
Forward Pharma A/S is a Denmark-based bio-pharmaceutical company. It is developing a proprietary formulation of dimethyl fumarate (DMF), for the treatment of multiple sclerosis (MS) and other inflammatory and neurological indications. DMF is an immunomodulator that can be used as a therapeutic to improve the health of patients with MS and immune disorders .The Company is headquartered in Copenhagen, Denmark.